Full text
Earnings transcript
Read the complete earnings call transcript.
USNA
USANA Health Sciences, Inc.
$19.04
0.03
(0.16%)
| Exchange: | NYSE |
| Market Cap: | 351.536M |
| Shares Outstanding: | 40M |
Delayed data
About The Company
| Sector: | Consumer Defensive | |||||
| Industry: | Packaged Foods | |||||
| CEO: | Kevin G. Guest | |||||
| Full Time Employees: | 1700 | |||||
| Address: |
| |||||
| Website: | https://www.usana.com |
USANA Health Sciences, Inc. specializes in the development, manufacturing, and direct sale of science-based nutritional supplements and personal care products. Its diverse product portfolio includes foundational nutrition, such as the Essentials/CellSentials vitamin and mineral supplements designed to support overall health across various age demographics. Complementing these are targeted optimizers addressing specific needs like cardiovascular, skeletal, or digestive well-being, alongside a range of food items including meal replacement shakes and snack bars. The company’s personal care line, Celavive, provides a comprehensive skincare regimen suitable for diverse skin types and ethnic backgrounds. Additionally, USANA offers specialized products catering to prenatal, infant, and young child age groups. To empower its independent associates, USANA provides extensive materials and online resources to facilitate business development and product marketing. Its products are distributed directly to consumers and online across key markets in the Asia Pacific region, the Americas, and Europe. Furthermore, USANA maintains research collaboration agreements with institutions like the Beijing University of Chinese Medicine for traditional Chinese medicine studies and the National Sports Training Bureau. Established in 1992, USANA Health Sciences, Inc. is headquartered in Salt Lake City, Utah.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 921,010 | 854,503 | 925,257 |
| Gross Profit | 731,615 | 678,752 | 724,405 |
| EBITDA | 123,110 | 98,861 | 82,071 |
| Operating Income | 93,071 | 66,324 | 50,862 |
| Net Income | 63,788 | 42,030 | 10,760 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 632,757 | 748,193 | 742,915 |
| Total Liabilities | 135,555 | 161,861 | 156,643 |
| Total Stockholders Equity | 497,202 | 532,109 | 533,104 |
| Total Debt | 13,205 | 29,013 | 14,000 |
| Cash and Cash Equivalents | 330,420 | 181,768 | 158,380 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 70,641 | 60,992 | 22,349 |
| Capital Expenditure | -14,494 | -10,073 | -13,823 |
| Free Cash Flow | 56,147 | 50,919 | 8,526 |
| Net Income | 63,788 | 42,060 | 10,760 |
| Net Change in Cash | 41,926 | -148,738 | -23,268 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2028 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,001,667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,001,667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,001,667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 126,419.596 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 126,419.596 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 126,419.596 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 51,449.982 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 51,449.982 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 51,449.982 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 615,885.602 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 615,885.602 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 615,885.602 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 2.770 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 2.770 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 2.770 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Performance: USANA reported an 11% year-over-year revenue increase in Q2 2025, as highlighted in the earnings call transcript, reflecting strong top-line growth. Key metrics such as net income and operating cash flow likely support this performance, indicating robust operational efficiency.
- Strong Balance Sheet: Based on balance sheet data, USANA maintains a healthy level of cash and cash equivalents relative to total current liabilities, suggesting liquidity strength. A low debt-to-equity ratio (if favorable per key metrics) further reinforces financial stability.
- Market Positioning: As part of the health and wellness industry within the consumer defensive sector, USANA benefits from consistent demand for health products, a trend supported by stable sector performance metrics over 1-year and 5-year periods.
- Product Innovation: The Q2 2025 earnings call emphasized enhancements in product offerings, which could drive customer retention and attract new market segments, bolstering competitive advantage.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates USNA intrinsic value between $22.58 – $39.10 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about USNA valuation
Is USANA Health Sciences, Inc. (USNA) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for USANA Health Sciences, Inc. (USNA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is USNA a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether USNA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is USNA’s P/E ratio?
You can see USNA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for USNA?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is USNA a good long-term investment?
Whether USNA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
USNA
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.16
Trading Metrics:
| Open: | 19.11 | Previous Close: | 19.01 | |
| Day Low: | 18.48 | Day High: | 19.36 | |
| Year Low: | 16.6 | Year High: | 38.32 | |
| Price Avg 50: | 18.46 | Price Avg 200: | 21.31 | |
| Volume: | 54156 | Average Volume: | 125076 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeUSNA full analysis
Welcome to MARKETSNAP’s SWOT analysis for USANA Health Sciences, a company that might not be on everyone’s radar but definitely deserves a closer look if you’re hunting for long-term investment opportunities. I’m thrilled to dive into this one with you today, breaking down the strengths, weaknesses, opportunities, and threats for this player in the health and wellness space. Let’s unpack what makes USANA Health Sciences tick, look at their recent performance, and figure out if this stock could be a…
